

STATE OF OKLAHOMA

2nd Session of the 57th Legislature (2020)

SENATE BILL 1273

By: Standridge

AS INTRODUCED

An Act relating to the Oklahoma Healthcare Authority;
requiring the Authority to conduct certain study;
requiring submission of certain report; defining
term; providing for codification; and providing an
effective date.

BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:

SECTION 1. NEW LAW A new section of law to be codified
in the Oklahoma Statutes as Section 5009.7 of Title 63, unless there
is created a duplication in numbering, reads as follows:

A. The Oklahoma Health Care Authority shall study the
feasibility of integrating pharmacogenomic testing into the state
Medicaid program for patients prescribed antipsychotic drugs. The
Authority shall submit a report to the President Pro Tempore of the
Senate, the Speaker of the House of Representatives and the Governor
on findings of the study. Such findings may include, but not be
limited to:

1 1. A recommendation on whether the state Medicaid program
2 should cover pharmacogenomic testing for patients prescribed
3 antipsychotic drugs; and

4 2. A cost-benefit analysis of covering pharmacogenomic testing
5 for patients prescribed antipsychotic drugs.

6 B. As used in this section, "antipsychotic drug" shall have the
7 same meaning as provided by Section 1-881 of Title 63 of the
8 Oklahoma Statutes.

9 SECTION 2. This act shall become effective November 1, 2020.

10
11 57-2-2488 DC 1/10/2020 6:28:49 PM
12
13
14
15
16
17
18
19
20
21
22
23
24
25